Fast Path To Market: Going From GMP1 To PPQ In Just 12 Months

Accelerating biopharmaceutical development without compromising quality requires more than compressed schedules — it demands disciplined execution, deep process understanding, and seamless global collaboration. This case-based perspective explores how a complex biologic advanced from initial GMP manufacturing to successful process performance qualification (PPQ) in just 12 months, significantly faster than conventional timelines. It highlights practical approaches to early process optimization, scale-up decision-making, and regulatory readiness, including how teams addressed unexpected challenges during downstream development.

Equally important, it illustrates how cross-site coordination, standardized quality systems, and clear governance can reduce risk while maintaining compliance with FDA expectations. The insights shared are especially relevant for organizations facing competitive pressure to reach the market first while managing technical uncertainty and operational complexity. Readers will gain a clearer understanding of what it takes to enable faster PPQ execution and how disciplined planning and collaboration can translate into real-world development gains.

Read the full white paper to explore the strategies behind this accelerated path to market.